<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02806752</url>
  </required_header>
  <id_info>
    <org_study_id>IRB2016006</org_study_id>
    <nct_id>NCT02806752</nct_id>
  </id_info>
  <brief_title>Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy</brief_title>
  <acronym>RANTA</acronym>
  <official_title>Multicenter Randomized Controlled Study of Intravitreal Ranibizumab and Triamcinolone Acetonide Combination Therapy Versus Ranibizumab Monotherapy in Patients With Polypoidal Choroidal Vasculopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aier School of Ophthalmology, Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aier School of Ophthalmology, Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects and safety of ranibizumab therapy
      combined with TA versus ranibizumab monotherapy in patients with polypoidal choroidal
      vasculopathy (PCV). Furthermore, the pharmacogenetics effect of inflammatory related genes
      polymorphism in response to the treatments. To further confirm the role of inflammatory
      factors in the pathogenesis and advance of PCV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polypoidal choroidal vasculopathy (PCV), a vascular disease of the choroid, appears to be the
      predominant subtype of exudative or &quot;wet&quot; AMD in Asian populations, in contrast to choroidal
      neovascularization secondary to AMD (CNV-AMD) in Western populations. There are distinct
      differences in pathophysiological, clinical and epidemiological factors between the two
      subtypes, although they also share some common risk factors. In contrast to CNV-AMD, PCV does
      not seem to respond as well to anti-VEGF treatment. The optimal treatment option for PCV
      remains elusive, with most studies showing good short-term visual outcome but poorer
      longer-term outcome with current treatment strategies. Therefore, understanding the
      pathogenesis of PCV, while developing novel and effective treatments strategies to prevent
      PCV-related vision loss is significant unmet needs.

      The purpose of this study is to assess the effects and safety of ranibizumab therapy combined
      with TA versus ranibizumab monotherapy in patients with PCV. Second, the pharmacogenetics
      effect of inflammatory related genes and polymorphism in response to the treatments of PCV
      will be explored. To further confirm the role of inflammatory factors in the pathogenesis and
      advance of PCV, it is important to determine the levels of inflammatory factors in the
      anterior chamber aqueous humor from PCV patients, comparing with the aqueous humor acquired
      from the age-matched age-related cataract patients undergoing phacoemulsification.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of mean BCVA</measure>
    <time_frame>12 months</time_frame>
    <description>Change of Central BCVA (Measured with EDTRS Chart,numbers of letters) (primary: baseline and 6 months, secondary: baseline to 12 months)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Central Rerina Thickness</measure>
    <time_frame>12 months</time_frame>
    <description>Change of Central Rerina Thickness (um) (primary: between baseline and 6 months, secondary: between baseline to 12 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>regression of Branch vacular network(BVN)</measure>
    <time_frame>12 months</time_frame>
    <description>Size of Branch vascular network (um)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polyps regression</measure>
    <time_frame>12 months</time_frame>
    <description>Size of polyps (um)(primary: between baseline and 6 months, secondary: between baseline to 12 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of re-treatments</measure>
    <time_frame>12 month</time_frame>
    <description>re-treatments numbers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Wet Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Ranibizumab + Triamcinolone Acetonide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravitreal injection: Ranibizumab 0.5mg + Triamcinolone Acetonide 2mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranibizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravitreal injection: Ranibizumab 0.5mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Acetonide</intervention_name>
    <description>Intravitreal inject 0.5mg of Ranibizumab and 2mg of Triamcinolone Acetonide.</description>
    <arm_group_label>Ranibizumab + Triamcinolone Acetonide</arm_group_label>
    <other_name>RANTA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Intravitreal inject 0.5mg of Ranibizumab.</description>
    <arm_group_label>Ranibizumab + Triamcinolone Acetonide</arm_group_label>
    <arm_group_label>Ranibizumab</arm_group_label>
    <other_name>RAN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  bestcorrected visual acuity (BCVA) letter score of 73 to 24 using Early Treatment of
             Diabetic Retinopathy Study charts at a starting distance of 4 m (20/40 to 20/320
             Snellen equivalent);

          -  a greatest lineardimensionof the lesion of &lt;5400 um( 9 Macular Photocoagulation Study
             disk areas), assessed by ICGA;

          -  Cross-reading by different center to conﬁrmed diagnosis of PCV, that is, presence of
             early subretinal focal ICGA hyperﬂuorescence (appearing within the ﬁrst 6 minutes
             after injection of indocyanine green) and in addition, at least one of the following
             angiographic or clinical criteria: (i) association with a BVN, (ii) presence of
             pulsatile polyp, (iii) nodular appearance when viewed stereoscopically, (iv) presence
             of hypoﬂuorescent halo (in ﬁrst 6 minutes),7 (v) orange subretinal nodules in
             stereoscopic color fundus photograph (polyp corresponding to ICGA lesions), or (vi)
             association with massive submacular hemorrhage (deﬁned as size of hemorrhage of at
             least 4 disk areas).

        Exclusion Criteria:

          -  received treatment previously with verteporﬁn PDT, focal laser photocoagulation,
             transpupillary thermotherapy, pneumatic displacement of subretinal blood, or any
             investigational treatment;

          -  a history of angioid streaks, presumed ocular histoplasmosis syndrome, or pathologic
             myopia;

          -  experienced RPE tear, retinal detachment, macular hole, or uncontrolled glaucoma;

          -  undergone intraocular surgery (except uncomplicated cataract extraction with
             intraocular lens implantation within 60 days before the screening visit)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shibo Tang</last_name>
    <role>Study Chair</role>
    <affiliation>Aier School of Ophthalmology, Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongjie Ma</last_name>
    <phone>+8613829716377</phone>
    <email>eyemhj@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Junyi Jiang</last_name>
    <phone>+8617773160741</phone>
    <email>ranta_study@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Aier Intech Eye Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Gu</last_name>
      <phone>+8613671276446</phone>
      <email>guwei530@126.com</email>
    </contact>
    <investigator>
      <last_name>Wei Gu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangzhou Aier Eye Hospital</name>
      <address>
        <city>Guanzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinglin Zhang</last_name>
      <phone>+8613560091515</phone>
      <email>zhjinglin@126.com</email>
    </contact>
    <investigator>
      <last_name>Jinglin Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hongjie Ma</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shenzhen Aier Eye Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuangnong Li</last_name>
      <phone>+8618925255595</phone>
      <email>lshuangnong@163.com</email>
    </contact>
    <investigator>
      <last_name>Shuangnong Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chen Lin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shenzhen Eye Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>528000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingshan Chen</last_name>
      <phone>+8613688805085</phone>
    </contact>
    <investigator>
      <last_name>Qingshan Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mingying Lai</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbin Aier Eye Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaomin Peng</last_name>
      <phone>+8613804558661</phone>
      <email>452115292@qq.com</email>
    </contact>
    <investigator>
      <last_name>Shaomin Peng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wuhan General Hospital of PLA</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanping Song</last_name>
      <phone>+8613871163802</phone>
      <email>songyanping@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Yanping Yanping</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhen Huang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Eye Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325027</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoling Liu</last_name>
      <phone>+8613758711161</phone>
    </contact>
    <contact_backup>
      <email>lxl@mail.eye.ac.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Xiaoling Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2016</study_first_submitted>
  <study_first_submitted_qc>June 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polypoidal Choroidal Vasculopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

